William Dahms, DO
Nephrology · Newark, DENPI 1952419376
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,678 of the $94,090 with a category attached, or 78.3%. 36 manufacturers reported payments, led by Vifor Pharma, Inc. at 38.7% of the total. Reporting peaked in 2022 at $32,953 and has fallen 91.9% since, to $2,656 in 2025. Among nephrology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 519 payments — averaging $181.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$36K
- Amgen$28K
- Bayer$13K
- Fresenius USA Marketing, Inc.$9K
- Otsuka America Pharmaceutical, Inc.$3K
- Mallinckrodt Hospital Products Inc.$981
- plus $4K from 30 others
What the payments were for
- Consulting fees$4,5225%
- Speaking & faculty fees$73,67878%
- Travel & lodging$3,9654%
- Food & beverage$11,51912%
- Education$4060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 61 | $36,455 |
| Amgen(2 entities) | 108 | $28,366 |
| Bayer | 41 | $12,576 |
| Fresenius USA Marketing, Inc. | 61 | $9,045 |
| Otsuka America Pharmaceutical, Inc. | 27 | $2,614 |
| Mallinckrodt Hospital Products Inc. | 31 | $981 |
| AstraZeneca(2 entities) | 32 | $647 |
| Calliditas Therapeutics US Inc. | 18 | $424 |
| Ardelyx, Inc. | 14 | $349 |
| Aurinia Pharma U.S., Inc. | 15 | $324 |
| Daiichi Sankyo Inc. | 12 | $210 |
| Novartis | 6 | $195 |
| Travere Therapeutics, Inc. | 11 | $192 |
| OPKO Pharmaceuticals, LLC | 11 | $190 |
| Akebia Therapeutics Inc | 8 | $176 |
| Lilly USA, LLC | 3 | $164 |
| Boston Scientific | 8 | $149 |
| Boehringer Ingelheim | 9 | $145 |
| Kyowa Kirin, Inc. | 6 | $115 |
| ANI Pharmaceuticals, Inc. | 4 | $109 |
| Sanofi | 5 | $92 |
| Medtronic | 1 | $85 |
| GSK | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Shield Therapeutics Inc | 1 | $55 |
| AMAG Pharmaceuticals, Inc. | 3 | $43 |
| Nxstage Medical, Inc. | 1 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $33 |
| Bard Peripheral Vascular, Inc. | 2 | $25 |
| Genentech USA, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Surmodics, Inc. | 3 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Daxor Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,090 in reported general payments places this provider in the 95th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TavneosAvacopan | 12 | $196,692 |
| JardianceEmpagliflozin | 17 | $26,312 |
| KerendiaFinerenone | 16 | $24,109 |
| RayaldeeCalcifediol | 13 | $17,253 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $14,240 |
| Torsemide | 248 | $4,041 |
| Eplerenone | 42 | $3,422 |
| Potassium Citrate ErPotassium Citrate | 32 | $2,372 |
| Sevelamer Carbonate | 14 | $2,025 |
| Losartan Potassium | 153 | $1,764 |
| Nebivolol Hcl | 11 | $1,371 |
| Allopurinol | 89 | $986 |
| Spironolactone | 56 | $844 |
| Chlorthalidone | 46 | $782 |
| Metoprolol Succinate | 24 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTavneos | $28,366 | $196,69212 claims |
| Boehringer IngelheimJardiance | $145 | $26,31217 claims |
| BayerKerendia | $12,576 | $24,10916 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $190 | $17,25313 claims |
| AstraZenecaLokelma | $647 | $14,24014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 nephrology providers in Delaware.
Other nephrology in Newark
- Prayus TailorNewark$127K
- Theodore SaadNewark$26K
- Nealanjon DasNewark$6K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Farhana ChowdhuryNewark$3K
- Feroz Abubacker KaniyamparambilNewark$3K
- Carlos MachadoNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.